Utilizing expanded neoantigen-specific T cells in PD-L1-deficient tumor-bearing mice led to the identification of neoantigens that sufficiently attenuated tumor growth following dendritic cell-based vaccines (Figure 3) [80]. The gene discussed is CD274; the disease is neoplasm.